

Denoising Search doubles the number of metabolite and exposome annotations in human plasma using an Orbitrap Astral mass spectrometer

Oliver Fiehn

ofiehn@ucdavis.edu

University of California, Davis <https://orcid.org/0000-0002-6261-8928>

Fanzhou Kong

University of California, Davis

Tong Shen

University of California, Davis

Yuanyue Li

UC Davis <https://orcid.org/0000-0001-5971-0355>

Amer Bashar

ThermoFisher Scientific

Susan Bird

ThermoFisher Scientific

Article

Keywords:

Posted Date: July 25th, 2024

DOI: <https://doi.org/10.21203/rs.3.rs-4758843/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: There is **NO** Competing Interest.

1 *Denoising Search* doubles the number of metabolite and exposome annotations in human plasma using 2 an Orbitrap Astral mass spectrometer

3 Fanzhou Kong^{1,2}, Tong Shen², Yuanyue Li², Amer Bashar³, Susan S. Bird³, Oliver Fiehn^{2*}

4
5 Affiliations:

6 ¹ Chemistry Department, One Shields Avenue, University of California Davis, Davis, CA, 95616, USA

7 ² West Coast Metabolomics Center, University of California Davis, Davis, CA, 95616, USA

8 ³ Thermo Fisher Scientific, 355 River Oaks Pkwy, San Jose, CA 95134, USA

9 **Abstract**

10 Chemical exposures may impact human metabolism and contribute to the etiology of neurodegenerative
11 disorders like Alzheimer's Disease (AD). Identifying these small metabolites involves matching experimental
12 spectra to reference spectra in databases. However, environmental chemicals or physiologically active
13 metabolites are usually present at low concentrations in human specimens. The presence of noise ions can
14 significantly degrade spectral quality, leading to false negatives and reduced identification rates. In response
15 to this challenge, the *Spectral Denoising* algorithm removes both chemical and electronic noise. *Spectral*
16 *Denoising* outperformed alternative methods in benchmarking studies on 240 tested metabolites. It improved
17 high confident compound identifications at an average 35-fold lower concentrations than previously
18 achievable. *Spectral Denoising* proved highly robust against varying levels of both chemical and electronic
19 noise even with >150-fold higher intensity of noise ions than true fragment ions. For human plasma samples
20 of AD patients that were analyzed on the Orbitrap Astral mass spectrometer, *Denoising Search* detected 2.3-
21 fold more annotated compounds compared to the Exploris 240 Orbitrap instrument, including drug
22 metabolites, household and industrial chemicals, and pesticides. This combination of advanced
23 instrumentation with a superior denoising algorithm opens the door for precision medicine in exposome
24 research.

25 **Introduction**

26 Human diseases are influenced by both genetic predispositions and environmental factors (GxE).
27 Environmental impacts, including diet, lifestyle, and biological and chemical exposures, account for over 70%
28 of disease incidence¹. However, chemical exposures in human samples are usually low abundant at trace
29 levels, similar to levels of physiologically active metabolites such as oxylipins, endocannabinoids or modified
30 bile acids^{2,3}. Nontargeted exposome research as well as metabolomics and lipidomics methods rely on liquid
31 chromatography coupled with high resolution mass spectrometry (LC-MS/MS)⁴. These small molecules are
32 identified by matching experimental spectra against established repositories like the NIST23 library,
33 MassBank of North America (MassBank.us), or GNPS/MassIVE^{5, 6}. While the quality of the experimental
34 spectra is critical for accurate MS/MS matching, mass spectra are often compromised by both electronic noise
35 and chemical noise⁷⁻⁹. This problem is particularly pronounced in metabolomics and exposome studies, where
36 the prevalence of low-abundance compounds can greatly exceed that of high-abundance compounds².
37 Electronic noise originates from the inherent characteristics of the electrical system, the discrete nature of ion
38 signals, or the process of Fourier transformation^{7,10}. Chemical noise is derived from components in the sample

39 that confound the signal generated by the metabolites and exposome compounds of interest⁹. Chemical noise
40 in LC-MS/MS is defined as isobaric interferences that emerge from the testing materials themselves, or from
41 laboratory consumables, solvents, cross-contaminations, buffers or carryovers⁹. The amalgamation of true and
42 contaminant fragment ions produces chimeric spectra. Chimeric spectra drastically affect spectral matching
43 scores and result in false negatives peak annotations, contributing to the ‘dark matter of metabolomics’^{11, 12}.
44 In proteomics, methods for noise removal resort to intensity modeling^{13, 14} and matching to in-silico spectra¹⁵.
45 In nontargeted small-molecule studies, methods were developed that required specific experimental
46 conditions to monitor the precursor-fragment ratios¹⁶, or leveraging database assistance^{17, 18}. Overall, these
47 methods provided only modest enhancements and low throughput. In addition, public datasets¹⁹ frequently
48 lack the experimental settings and database metadata required for these methods. Consequently, existing
49 denoising methods are unsuitable for large scale, standardized de-noising in metabolomics. Typical
50 metabolomics data processing software denoises spectra by simply discarding ions below 0.5-1% of the base-
51 peak height²⁰⁻²². Surprisingly, the chemistry information revealed by the fragment peaks are not considered
52 when determining if a given fragment is true ion or noise. We here show that integrating intensity modeling
53 with assessing chemical plausibility greatly enhances the effectiveness of noise ion removal, termed *Spectral*
54 *Denoising*. *Spectral Denoising* first eliminates electronic noise by stratifying fragment ion intensities,
55 followed by filtering the remaining fragments based on their chemical plausibility as true fragments of the
56 molecular formula of the precursor ion. Utilizing a 13-stage series dilution dataset of 240 small molecules
57 generated an experimental benchmarking dataset with varying levels of spectral quality. This dataset was used
58 to rigorously benchmark the robustness of *Spectral Denoising* against other methods, including by virtually
59 adding different levels of contaminating chemical and electronic noise ions. False discovery rates (FDR) were
60 thoroughly tested against 1,267 experimental spectra that were annotated by NIST23, MassBank.us and GNPS
61 libraries. By integrating *Spectral Denoising* into the spectral matching process (*‘Denoising Search’*), we
62 evaluated its performance using human plasma samples from AD patients acquired with advanced
63 Asymmetric Track Lossless (Astral) mass spectrometry and classic Orbitrap instruments. The number of
64 annotated compounds increased more than 2-fold with *Denoising Search* compared to classic compound
65 annotation pipelines. By combining Astral mass spectrometry and *Denoising Search*, low-abundance
66 exposome compounds can be detected in human plasma that have not been reported before in the literature.
67 Hence, *Denoising Search* may herald a new era in the identification of key biomarkers, more confident
68 compound annotations and better interpretability of datasets that are critically needed for biomedical research
69 like neurodegenerative diseases.

70 **Results**

71 Figure 1 gives the schema of how the *Spectral Denoising* algorithm removes ions recorded in collision-
72 induced MS/MS spectra that do not represent genuine fragments of the precursor ion. The first step removes
73 electronic noise that commonly appears as a multitude of (low-abundant) ions with very similar intensities,
74 also termed ‘grass noise’²³. Chemical noise is harder to recognize because it is generated by co-isolating and
75 fragmenting non-target precursor ions in low-resolution quadrupole mass filters that precede the collision-
76 induced dissociation even in high-resolution mass spectrometers²⁴. In practice, the isolation window used in
77 most metabolomics studies ranges from 1 to 5 Da, increasing the likelihood of inclusion of contaminant ions
78 due to isobaric interference²⁵. These chemical noise ions can vary widely in intensity, making them difficult
79 to distinguish from true fragment ions by manual inspection alone⁹. Hence, our schema to remove chemical
80 noise ions is based on the unique property of true fragment ions to produce a chemically plausible neutral loss
81 (or radical losses), calculated from the accurate mass of the target precursor ion²⁶ (Figure 1).

82 To test this concept, we first empirically
83 probed all 230,000 MS/MS spectra of the
84 NIST23 library that was generated by the U.S.
85 National Institute of Standards and Technology
86 through a rigorous validation and fragment
87 verification process to guarantee a high fidelity
88 of data quality. For more than 99.5% of all ions
89 per spectrum, fewer than four ions were found
90 within relative intensities of $\pm 0.1\%$ (Extended
91 Figure 1). This data served as valid threshold to
92 automatically identify electronic noise ions in
93 experimental MS/MS spectra and remove these
94 ions, independent of the relative intensity (Figure
95 1A).

96 Electronic denoising differs in two key
97 aspects from simply discarding ions below a pre-
98 defined threshold. First, ions are not discarded
99 simply based on relative intensity levels. In this
100 way, electronic denoising retains low-abundant
101 ions that may represent true fragment ions of the
102 precursor molecule. This step is important because many small molecules do not produce fragment-rich
103 spectra, unlike peptides, covered in the new concept of spectral entropy^{21, 27}. The denoised MS/MS example
104 spectrum in 1.4 (Figure 1) would calculate $S=1.9$, compared to a more disordered contaminated spectrum 1.1
105 with $S=3.3$ before the denoising process. Second, electronic noise becomes relatively more prominent for
106 MS/MS spectra that originated from very low-intensity precursor ions. Therefore, a simple cut-off threshold
107 at 1% base peak intensity does not suffice for metabolomics or exposome nontargeted studies that aim at low
108 abundant molecules^{20, 22}.

109 Subsequently, chemical denoising identifies and removes chemical noise ions by calculating whether
110 the exact mass of each fragment can logically be associated with a subformula loss from the parent molecular
111 ion species (Figure 1B). The chemical plausibility of relative loss subformulas was validated using the Seven
112 Golden Rules algorithm to discard chemically impossible losses (e.g., CH_{12})²⁸ while ignoring the LEWIS and
113 SENIOR checks that are designed for intact molecules. In collision-induced dissociation, a fragment ion can
114 result from multiple relative losses from the precursor ion, potentially violating the SENIOR rule²⁹.

115 Instead, chemical denoising expands the logic of our subformula-loss calculations of chemical noise
116 ions. For example, radical fragment ions are formed in about 10% of small molecule MS/MS spectra as
117 metastable state in mass spectrometry, even for even-electron precursors³⁰. Enforcing the LEWIS rule would
118 lead to the removal of these valid radical fragment ions³⁰. Moreover, about 1% of MS/MS spectra were
119 reported in which the collision gas nitrogen formed bonds with substituted aromatic compounds within the
120 collision cell, with subsequent background water substitution^{31, 32}. We confirmed the occurrence of such
121 fragmentations in the NIST23 spectral library and validated these experimentally in our laboratory. Hence,
122 *Spectral Denoising* accounts for possible $[\text{M}+\text{N}_2+\text{H}_2\text{O}]$ molecule reactions when calculating the relative loss
123 of fragment ions for substituted aromatic compounds. The sequential combination of electronic and chemical
124 denoising was validated on 10,000 NIST23 spectra and compared MS/MS similarities of the denoised against
125 the original library spectra (Extended Figure 2). Entropy similarity is scaled in the same manner as classic
126 dot-score similarities, from 0-1 with 1 marking perfect matches and 0 giving no similarity at all. If no ions




Figure 1. Flowchart for *Spectral Denoising*.

(a) Removing electronic noise by recognizing repeated fragment ions with identical intensities.

(b) Removing chemical noise by identifying remaining fragment ions that do not fit possible elemental subformulas from the precursor ion mass. The dotted line indicates the precursor ion m/z .

127 were removed by the denoising algorithm, MS/MS similarities would remain identical, leading to perfect
128 matching scores of 1. In all calculations, the remaining abundance of the precursor ion intensities is ignored
129 to focus entirely on genuine fragment spectra, and because all identity-search algorithms already exclude
130 compounds that do not match specific accurate mass windows of the precursor mass (typically at 5 ppm). The
131 average similarity of the selected denoised NIST23 spectra was >0.99, proving that the denoising method did
132 not accidentally remove true ions, and that the NIST23 spectra have very high quality (Extended Figure 2).


133 *Denoising experimental MS/MS spectra of 240 metabolites diluted from 500-0.02 pmol injections*

134 To evaluate the effectiveness of our denoising strategy, we analyzed 240 metabolites in both positive and
135 negative electrospray ionization (ESI) modes in a 13-step serial dilution from 500 pmol to 0.02 pmol injected
136 onto the column. MS/MS spectra of the most concentrated 500 pmol injections represented optimal spectral
137 quality, while the more diluted ones were expected to gradually deteriorate in spectra quality due to an
138 increased contribution of contaminating noise ions. A total of 28 compounds were excluded due to insufficient
139 fragmentation with less than two fragment ions (spectral entropy <0.5). The remaining dataset of MS/MS
140 spectra that were used for MS/MS similarity calculations included a total of 11,823 spectra, encompassing
141 6,885 in the positive mode and 4,938 in the negative ESI mode (Extended Figure 3).

142 First, the ability of the denoising algorithm was evaluated to discern noise ions from genuine fragment ions.
143 To this end, the total explained ion intensity was enumerated as metric to quantify the proportion of true ion
144 intensities in each spectrum (Figure 2a). The probability density of explained ion intensities shifted markedly
145 from high to low amounts of injected compounds, highlighting the effectiveness of the denoising algorithm
146 to identify noise ions. The probability distributions of the calculated entropy similarities (Figure 2b) showed
147 and even more pronounced decrease in median MS/MS similarities with lowered injected amounts, from
148 >0.92 entropy similarity at 200 pmol injected to <0.41 median similarity at the lowest injection quantities.
149 Remarkably, at 1 pmol injections (about 0.3 ng injected onto the column, at the median molecular mass of the
150 chemicals included test mixture), more than 50% of all MS/MS spectra already failed to match the reference
151 spectra at entropy similarity > 0.75, a cut-off that is often used in metabolite annotations in metabolomics
152 (Figure 2b). More importantly, the *Spectral Denoising* algorithm effectively removed chemical and electronic
153 noise ions for all test compounds (Figure 2c). As expected, the largest improvement for MS/MS similarity
154 calculations were observed for very low injected amounts with a median gain of 0.18 entropy similarity scores.
155 At 1 pmol injections, a median improvement of 0.1 MS/MS entropy similarity gain was noted, and even for
156 200 pmol injections, 25% of the compounds already showed an improvement of entropy similarities of 0.05
157 (Figure 2c). Example spectra are depicted in Figure 2d with the precursor ions given as dotted lines to indicate
158 that residual precursor mass intensities were ignored in MS/MS similarity calculations. For 3,4-didesmethyl-
159 5-deshydroxy-ethoxyscleroïn and enoxolone, raw spectra MS/MS of low abundant injections were notably
160 marred by substantial electronic noise with up to 30% relative base peak intensity, vastly exceeding the typical
161 1% base peak ratio often used as a threshold (Figure 2d). For spermidine injected at 0.04 pmol, the initial raw
162 spectrum displayed a diverse set of ion intensities without obvious signs of electronic noise. Surprisingly, the
163 three most abundant ions m/z 86.004, m/z 95.009, and m/z 108.494 were identified as chemical noise,
164 compromising the entropy similarity to a level of 0.24 score. The denoised spermidine spectrum showed a
165 perfect match with an entropy similarity of 0.95 (Figure 2d).

166 Next, the efficiency of *Spectral Denoising* was evaluated by benchmarking its performance against three
167 established MS/MS denoising techniques: the classic 1% base peak height thresholding method^{20, 22}, dynamic
168 noise level (DNL) denoising¹⁴, and MS Reduce denoising¹³. The benchmarking dataset comprised all 2,677

169 spectra that had raw MS/MS similarities <0.75 score, meaning they might not be annotated by high confidence
 170 identification schemas (Figure 2e). Similar to *Spectral Denoising*, the three methods selected for
 171 benchmarking purpose are standalone tools with a generalized scope of applicability, as they do not
 172 necessitate complementary metadata or additional experimental setups. While we initially hypothesized that
 173 all denoising methods might enhance spectral matching, neither of the three benchmarked algorithms showed
 174 any marked improvement. DNL denoising yielded only a slight improvement in entropy similarity for a
 175 limited subset of spectra, with a modest increment of 0.01 in spectral similarity. The MS Reduce approach,
 176 even at the highest quantization level of 11¹³, failed to enhance spectral similarity effectively. Surprisingly,
 177 even the classic 1% base peak thresholding method showed negligible impact on spectral similarity matching,
 178 indicating that while simple and computationally inexpensive, this method is inadequate for noise ion removal
 179 in low-abundance compound spectra. In contrast, our *Spectral Denoising* method showed significant gains
 180 for MS/MS spectral matching with a median entropy similarity increase of 0.17, lifting more than 1,500
 181 spectra to MS/MS similarity >0.75 and thereby boosting the compound annotation rates by 30% (Figure 2e).



182
 183 **Figure 2.** Developing, validating and benchmarking the *Spectral Denoising* algorithm. **(a)** Probability density
 184 distribution (explained denoised/raw intensities) of all MS/MS spectra from 240 injected standards between 0.02-500
 185 pmol. **(b)** Probability density distribution of the entropy similarities before *Spectral Denoising* of all MS/MS spectra
 186 from 240 injected standards between 0.02-200 pmol, using the 500 pmol spectra as reference. **(c)** Improvement in spectral
 187 entropy similarities after *Spectral Denoising*. **(d)** Examples of head-to-tail plots of MS/MS spectra before and after
 188 *Spectral Denoising* for compounds injected at low quantities. **(e)** Cumulative distribution of MS/MS entropy similarities
 189 before ('raw') and after applying three benchmarking methods against the *Spectral Denoising* algorithm. Only raw
 190 spectra with MS/MS entropy similarities <0.75, a typical threshold for automatic metabolite annotations. **(f)** Strip plot

191 to visualize absolute improvements in MS/MS similarities across three benchmarking methods and the *Spectral*
192 *Denoising* algorithm.


193 A second benchmarking test quantified at how much lower injected quantities compounds could be annotated
194 at entropy similarity >0.75 by applying the *Spectral Denoising* method. For all 181 compounds that were
195 detected in at least more than one dilution stage (Supplement 1), the fold-change was calculated between the
196 lowest injected amount that reached >0.75 entropy similarity for the raw MS/MS spectra, compared to the
197 lowest injected amount after *Spectral Denoising* (Figure 2f). On average, our *Spectral Denoising* method
198 required 35-fold lower molar quantities injected onto the column (Figure 2f, Supplement 1), while not a single
199 compound failed to be annotated after *Spectral Denoising* (no false negatives). In contrast, all other denoising
200 techniques showed minimal improvements for annotations injected at lower absolute quantities. Specifically,
201 the 1% base peak thresholding method demonstrated no enhancement for 163 compounds. Similarly, DNL
202 denoising and MS Reduce only showed improvements for so-few compounds. More concerningly, both DNL
203 denoising and MS Reduce did not only fail to improve quantity thresholds for successful MS/MS annotations
204 but instead detrimentally affected spectral matching. For MS Reduce, 108 compounds became unannotated
205 (false negative) even at the same concentration level after processing the raw MS/MS spectra. For DNL
206 denoising, this number of false negatives was 86 compounds. This indicates that both methods inadvertently
207 removed true fragment ions, thereby shifting entropy similarity distributions to lower values across all spectra
208 (Extended Figure 4). This disparity in performance across denoising techniques may originate from their
209 foundational assumptions, as both DNL and MS-reduce were introduced on proteomics data that are usually
210 fragment-rich, unlike in metabolomics where collision-induced fragments spectra are usually sparse. Thus,
211 the underlying assumptions of the DNL- and MS-reduce intensity modeling-based denoising methods are no
212 longer valid when applied to metabolomics data, highlighting the necessity for specialized approaches in this
213 field.

214 *Applying Spectral Denoising against artificial noise ions*

215 Contamination by noise ions in experimental spectra from biological samples is more challenging than the
216 sets of chemical standards shown above. A larger diversity of noise origins, e.g. from the chemosphere of the
217 exposome, requires better mimicking large-scale contribution of different types of noise. To thoroughly assess
218 the robustness of the tested denoising algorithms, the 0.01-200 pmol dilution series experimental spectra were
219 used to create artificial chimeric spectra by adding simulated levels of chemical and electronic noise. Both
220 types of noise ions were introduced using established noise models⁸, albeit with different parameter sets to
221 accurately reflect their characteristics. Chemical noise, characterized by real chemical formulas, typically
222 appears with high intensity but low ion counts. The mass-to-charge ratios of chemical noise ions were sampled
223 from a database of 3.5 million authentic chemical formulas³³, with their relative intensities determined using
224 the noise model with a mean intensity of 50% of the base peak height. We defined three contamination levels
225 for chemical noise, with the total noise ion counts to raw ion counts in a ratio of 1:10 (low), 2:10 (medium),
226 and 5:10 (high). Electronic noise typically manifests as low-intensity but high-quantity 'grass noise'²³. Thus,
227 the mass-to-charge ratios of electronic noise ions were randomly sampled, with their relative intensities
228 determined by the same noise model mean ion intensity of 5% base peak height. Similarly, we also designed
229 three levels of electronic noise contamination: low (2:1), medium (10:1), and high (100:1), yielding nine tests
230 of combined noise levels.

231 The resulting chimeric spectra were matched against the 500 pmol benchmark spectra of the authentic
232 standards, and denoised with *Spectral Denoising*, MS Reduce, DNL denoising and 1% bp thresholding


233 (Figure 3). The distribution frequency plot of all combined raw spectra of the compound dilution series yielded
 234 a median entropy similarity of 0.8, with an average of 0.71 and a mode at 0.95 (Extended Figure 4). Adding
 235 virtual noise to render chimeric spectra drastically reduced the spectral quality in all nine test scenarios, even
 236 for the lowest level of chemical and electronic noise (Figure 3), to a mode of 0.5 spectral entropy. When
 237 considering the mode points in the frequency distributions of the raw spectra, electronic noise worsened
 238 spectral entropy scores more dramatically than chemical noise additions, even at low levels of electronic noise.
 239 For all nine test cases, our denoising method restored the frequency distributions of the contaminated spectra
 240 above the levels of the original spectra, with the median spectral entropy similarity ranging from 0.71 (high
 241 electronic, high chemical noise) to 0.87 (low electronic, low chemical noise) (Figure 3). Importantly, the
 242 benchmarking test clearly demonstrated that none of the other algorithms came close to the performance of
 243 our *Spectral Denoising* method (Figure 3), with the best frequency modes located at spectral entropy 0.6 for
 244 the MS Reduce method for the low electronic, low chemical noise test scenario.



245

246 **Figure 3.** Probability distributions of MS/MS entropy similarities before ('raw') and after applying three benchmarking
 247 methods against the *Spectral Denoising* algorithm, under varying levels of artificially added chemical and electronic
 248 noises. Chemical noise: *Level 1:10* added at least one noise ion for every 10 experimental ions; *Level 1:5* added at least
 249 one noise ion for every 5 experimental ions; *Level 1:2* added at least one noise ion for every 2 experimental ions.
 250 Electronic noise: *Level 2:1* added two noise ions per experimental ion; *Level 10:1* added ten noise ions per experimental
 251 ion; *Level 100:1* added one hundred noise ions per experimental ion.

252 Overall, neither the 1% bp thresholding nor the DNL denoising approaches yielded any substantial
 253 improvement across any level of chemical noise contamination (Figure 3). Last, we investigated if the
 254 improvement of MS/MS similarities by *Spectral Denoising* depended on the entropy of the 500 pmol
 255 reference spectra themselves. Spectra were categorized into five groups, from 0-1 entropy (low number of
 256 fragment ions) to 4-5 entropy levels (high number of fragment ions with varying intensities). We suspected
 257 that most experimental spectra from biological samples would only be subjected to minor to moderate
 258 contamination and therefore only used mid-level and low-level combinations of virtually added noise ions.
 259 As expected, reference raw spectra that started with lower entropy (0-1) benefitted the most from *Spectral*
 260 *Denoising*, as such spectra also see the most dramatic decline in MS/MS spectral similarities when noise ions
 261 are added (Figure 4). Conversely, reference raw spectra with high spectral entropy ($S > 4$) better tolerate the
 262 addition of noise ions, and hence benefit a little less from *Spectral Denoising* (Figure 4). Yet, mass spectra
 263 from any starting entropy levels showed clear improvements in MS/MS similarity from *Spectral Denoising*
 264 when artificial noise was added, with a frequency distribution mode of 0.42 similarity improvements for $S=4$ -
 265 5 spectra and middle levels of added noise, and 0.2 similarity improvements at low levels of added noise
 266 (Figure 4). The results for the remaining seven sets of entropy similarity improvements are given in Extended
 267 Figure 5. Overall, these sets of benchmarking and noise-addition experiments clearly demonstrates that our
 268 *Spectral Denoising* method outperforms all other techniques and is extremely robust across varying levels of
 269 chemical and electronic noise contamination.



270
 271 **Figure 4.** Density distributions for MS/MS similarity improvements after *Spectral Denoising* for all MS/MS spectra
 272 from 240 injected standards between 0.02-200 pmol, using the 500 pmol spectra as reference. Chemical standards were
 273 grouped into five sets with different starting spectral entropies (blue to purple). **(a)** MS/MS similarity improvements for
 274 spectra to which contamination ions were artificially added at '*mid-levels*', Level 10:1 electronic noise, and Level 1:5
 275 chemical noise. **(b)** MS/MS similarity improvements for spectra to which contamination ions were artificially added at
 276 '*low levels*', Level 2:1 electronic noise and Level 1:10 chemical noise.

277 *Development and applying Denoising Search on HILIC-MS/MS data from the plasma of AD patients*

278 In the prior experiments, all test spectra had a priori knowledge of the molecular formula information.
 279 Although today's algorithms are capable of annotating molecular formulas from MS/MS spectra of reference
 280 compounds with >95% confidence^{33, 34}, these tests have never been conducted on low abundant or noisy
 281 spectra. To enhance the applicability of our denoising method, *Spectral Denoising* was integrated into the
 282 spectra searching process, now termed '*Denoising Search*.'

283 *Denoising Search* starts by denoising the experimental spectra using all molecular formulas that fall within
 284 the predefined precursor mass accuracy, i.e. not assuming a single starting formula. As it is a spectral identity
 285 search algorithm, it depends on the formula space that is being searched. In combination, MassBank.us, GNPS
 286 and NIST23 contain 2,028,556 experimental spectra, corresponding to 435,698 compounds and 37,493
 287 formulas. When restricting the search space in this way, spectral matching scores for the *Denoising Search*
 288 were calculated based on all denoised spectra that fit the formula criteria within the mass accuracy of the
 289 instrument. For practical
 290 reasons, a 10 mDa mass
 291 accuracy threshold was used
 292 although Orbitrap instruments
 293 are known to yield much better
 294 exact masses (i.e., sub-ppm with
 295 internal calibration). However,
 296 for low abundant ions, mass
 297 accuracy levels suffer in
 298 concordance with compromised
 299 ion statistics. Essentially,
 300 *Denoising Search* functions
 301 similarly to a Bayesian
 302 probability approach, evaluating
 303 how likely it is to observe the
 304 query spectra with all potential
 305 chemical and electronic noise
 306 removed, given a specific target
 307 compound. The rationale is that
 308 if the correct molecular
 309 information is used to denoise
 310 the spectra, noise ions will be
 311 accurately identified and
 312 removed, thereby improving
 313 spectral matching scores.
 314 Conversely, if the molecular
 315 formula information is incorrect,
 316 the fragment patterns will be
 317 vastly different, and the removal
 318 of true ions would lower the
 319 entropy similarity scores, still
 320 resulting in true negative
 321 annotations. This rationale was
 322 validated by testing the false
 323 discovery rate (FDR) of
 324 *Denoising Search* against simple entropy similarity identity search on an in-house validation dataset with
 325 extensive manual curation (Extended Figure 6). At an entropy similarity level of 0.75, the two methods
 326 showed <1% differences in terms of the FDR rate, indicating that *Denoising Search* did not introduce
 327 unwanted bias or false positives (Extended Figure 6).




Figure 5. *Denoising Search* results for positive ESI mode HILIC-MS/MS data acquired on an Exploris 240 Orbitrap instrument and the Astral mass spectrometer, using 20 plasma samples of Alzheimer's disease patients. **(a)** Improvement of metabolite annotations at MS/MS similarity >0.75 before and after *Denoising Search* using MassBank.us, GNPS and NIST23 libraries. **(b)** Cumulative probability density before and after *Denoising Search* for Astral mass spectrometry spectra. **(c)** Proportions of metabolite annotations after *Denoising Search* at MS/MS similarity >0.75 for different chemical superclasses using the Exploris 240 Orbitrap (inner ring) or the Astral mass spectrometer (outer ring). **(d)** Head-to-tail plots for four selected compounds annotated uniquely on Astral data after *Denoising Search* (blue) against library spectra (red).

328 To evaluate the performance of *Denoising Search* on experimental spectra of human patient samples, a small
329 pilot plasma study was used comparing two high-resolution, accurate mass instruments: the classic Orbitrap
330 Exploris 240 mass spectrometer and a new instrument introduced in 2023, the Orbitrap Asymmetric Track
331 Lossless (Astral) mass spectrometer. The Astral mass analyzer acquired 17 times more spectra in each scan
332 cycle compared to the Exploris 240 instrument, resulting in 5-times more MS1 m/z-retention time features
333 that had corresponding MS/MS spectra. In effect, the Astral instrument provided a top-35 data dependent
334 analysis MS/MS survey, surpassing the Exploris 240 instrument that only used a top-2 DDA mode. While the
335 Orbitrap Astral instrument had previously shown its superior capabilities in proteomics studies, this
336 comparison demonstrates its advantages for metabolomic tests. Overall, the raw spectra from the Astral
337 analyzer achieved 60% more annotations than those from the Exploris 240 mass spectrometer when matching
338 spectra against the NIST23, MassBank.us and GNPS libraries (Figure 5a). For the Exploris 240 instrument,
339 *Denoising Search* facilitated an additional 22% increase in annotations, while *Denoising Search* yielded a
340 45% increase in annotated compounds over the raw spectra for the Astral mass analyzer (Figure 5a). Hence,
341 compared to the raw Exploris MS/MS spectra, the *Denoising Search* on Astral data led to 2.3-fold more
342 annotations, including many exposome compounds that were not found on the Exploris Orbitrap instrument.
343 Notably, using *Denoising Search*, a significant increase of 0.11 median MS/MS entropy similarity was
344 achieved for Astral spectra that showed raw entropy similarity ≥ 0.4 (Figure 5b). A closer examination of the
345 seven main ClassyFire compound superclasses revealed a notable increase in the number of annotations across
346 all superclasses on denoised Astral spectra compared to those found with Exploris (Figure 5c). Superclasses
347 such as organic acids and derivatives fully leveraged the capabilities of the Astral, resulting in a 2.2-fold
348 increase in annotated compounds, while organoheterocyclic compounds saw an 89% increase in annotated
349 compounds. A significant increase in the number of MS/MS spectra was acquired by Astral Orbitrap mass
350 spectrometry, thanks to its high sensitivity and its unprecedented acquisition speed (up to 200 Hz in DIA
351 mode, 160 Hz in DDA mode). By combining our *Denoising Search* with Astral mass spectrometry, several
352 compounds were identified that were previously underexplored in human blood (Figure 5d). Beyond drugs
353 like threo-dihydrobupropion and N-(4-chlorophenyl)-3-phenylpropanamide, Irganox 565, a hindered phenol
354 antioxidant, was reported in human blood for the first time, despite its prior detection in environmental dust
355 samples³⁵. This pilot study demonstrates that the advancement of mass analyzers allows for the acquisition of
356 more spectra, and the *Denoising Search* is crucial for fully taking advantage of these extra spectra triggered
357 by precursors across a wide range of magnitudes.

358 **Discussion**

359 The impact of noise ions in spectra of low-abundance compounds is well-recognized in metabolomics and
360 exposome research. These ions complicate chemical annotations, contributing significantly to the
361 accumulation of 'dark matter' in small-molecule research. We here employed a strategy combining intensity
362 modeling and subformula assignments to effectively eliminate noise ions while preserving essential true
363 fragment ions, even at low relative intensities. Using a 13-stage dilution of MS/MS spectra of genuine
364 chemical reference standards as a ground truth dataset, demonstrated a superior ability for the *Spectral*
365 *Denoising* algorithm to identify and remove noise ions. Noise removal notably enhanced MS/MS entropy
366 similarities, particularly for spectra that were injected at low absolute quantities. Low abundant peaks
367 represent the large majority of unknown compounds in metabolomic studies, rendering *Denoising Search* as
368 a promising tool for major improvements in metabolome and exposome coverage.

369 We benchmarked our method against three alternative denoising algorithms. *Spectral Denoising* consistently
370 outperformed the benchmarked alternatives, improving both the entropy similarity and the absolute quantity
371 limit of high-confidence compound annotations. Despite varying levels of artificial noise, our method
372 maintained robust performance. However, not all added noise ions were removed, primarily because our
373 chemical plausibility checks were limited to the algorithms embedded in the Seven Golden Rules method²⁸,
374 without considering molecular connectivity. Alternative approaches for recognizing true fragment ions
375 involve the application of substructure annotation tools. Current software, such as Sirius³⁴, and MS-FINDER³⁶,
376 often fails to recognize radical losses, which are prevalent in small molecule spectra (affecting over 60% of
377 even-electron precursors spectra in NIST20)³⁰. Without recognizing radical losses, true fragment ions may
378 potentially be discarded. Therefore, subformula assignments that preserve valuable true fragment ions should
379 be preferred over substructure annotation tools.

380 Yet, inherent limitations persist when solely relying on MS/MS spectra for compound annotation, even after
381 removing noise ions. Reference spectra with inherently low spectral entropy are particularly vulnerable to
382 noise ions, potentially leading to false negatives. The inability to differentiate between isomeric compounds
383 and in-source fragments also presents significant challenges for the annotation of compounds in metabolomics
384 when solely relying on MS/MS spectral matching. These observations indicate that employing hard
385 thresholding based exclusively on spectral similarity is suboptimal for compound annotation in metabolomics
386 and exposome research. Instead, *Denoising Search* should be supplemented with orthogonal experimental
387 measures, such as retention time matching³⁷, molecular cross-section comparisons³⁸, and biological metadata
388 screening³⁹, to further enhance the confidence of compound identifications in small molecule research. When
389 applied to the latest ThermoFisher Scientific instrument, the Astral mass spectrometer, *Denoising Search*
390 facilitated a 2.3-fold increase in the number of annotated compounds compared to classic MS/MS similarity
391 investigations on an Exploris 240 mass spectrometer, with improvements noted across all seven major
392 chemical superclasses.

393 **Methods**

394 *Spectral Denoising*

395 High-resolution mass spectra utilized for the development and validation of our *Spectral Denoising* algorithm
396 were sourced from the licensed NIST23 Tandem Mass Spectral Library (2023 release). The explained ion
397 intensity was calculated as the ratio of ion intensity retained post-denoising, denoted as, $I_{p,valid}$, to the total
398 ion intensity of raw spectra, I_p , as demonstrated in equation (1):

$$399 \quad \text{Explained intensity (\%)} = \frac{\sum_{p,valid} I_{p,valid}}{\sum_p I_p} \quad (1)$$

400 Figure 1 (main text) visualizes the schema of the *Spectral Denoising* pipeline. All spectra were subjected to
401 precursor removal before applying any form of *Spectral Denoising*, to ensure that residual intensities of the
402 precursor ions do not inflate MS/MS matching scores.

403
404 Acquiring serial dilution MS/MS data of reference compounds to validate *Spectral Denoising*
405 Stock solutions of all target chemicals were prepared at 10 mM concentrations in methanol. Six mixtures of
406 non-isobaric standards, each containing 40 compounds, were prepared by mixing 2.27 μL of each standard to
407 achieve a concentration of 0.25 mM. 13 dilutions from these stock solutions were made to obtain final amounts
408 to be injected into the LC-MS/MS systems, ranging from 0.02 pmol to 500 pmol: 0.02, 0.04, 0.1, 0.2, 0.4, 1,

2, 4, 10, 40, 100, 200 and 500 pmol (the concentration of the stock solution). Prior to injections, solutions were dried and resuspended in 100 μ l of the LC starting buffer. 2 μ l volumes were injected onto a 10 cm, 2.1 mm i.d., 1.7 μ m particle Waters Acquity BEH amide column maintained at 30 $^{\circ}$ C with a flow rate of 0.4 mL/min, utilizing a gradient of mobile phases of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B)⁴⁰. Mass spectrometric detection was carried out on a Thermo Q- Exactive HF Orbitrap instrument (ThermoFisher Scientific, San Jose, CA) operated in positive electrospray ionization mode. Mass spectrometry was performed from a mass range 60-1500 m/z with a sheath gas flow rate 60, auxiliary gas flow rate 25, sweep gas flow rate 2, spray voltage 3.6 kV, capillary temperature 300 $^{\circ}$ C, S-lens RF level 50, and an auxiliary gas heater temperature 370 $^{\circ}$ C. MS¹ settings were set at a resolving power R=70,000, an automatic gain control target of 1e6, and a maximum injection time of 100 ms for single scans in centroid mode. MS/MS data were acquired in data-dependent mode at a resolving power R=15,000, an AGC target of 1e4, and a maximum injection time of 100 ms, with an isolation window of 1.0 m/z and no offset. The Top-N setting was 4, with an MSX count 1, loop count 4, and normalized collision energy steps 25, 35, and 65 NCE in centroid mode. For each mixture, precursor ions of the target compounds were specifically included for MS/MS acquisition as separate target inclusion lists to ensure that MS/MS spectra were acquired even for very low injected amounts, for which MS¹ ion intensities may not have been found within the top-4 most abundant ions in an MS¹ spectrum. Feature detection was performed on MS 4.9.2.

426

427 *Benchmarking Spectral Denoising against alternative denoising algorithms*

428 Algorithms were obtained from literature based on their premise to remove noise ions in MS/MS spectra and
429 to promote spectral annotations. Methods were excluded if they relied on data integration across multiple
430 spectra ('consensus spectra') or if they required auxiliary instrumentations^{16, 17}. Three alternative denoising
431 algorithms were implemented in Python 3.8. The reducing factor used for MS Reduce denoising was 90 with
432 the maximum allowed quantization level of 11. For threshold denoising, the widely used 1% base peak height
433 was selected as the predefined noise level. DNL denoising algorithm does not require additional parameter
434 settings. The performance of the denoising algorithms was benchmarked on the 240 metabolite standards with
435 absolute injected volumes from 200 pmol to 0.02 pmol, using the 500 pmol spectra as reference spectra. The
436 improvements of MS/MS similarities for low abundant compounds were calculated using the ratio of the
437 lowest injected quantity of compounds that yielded an MS/MS entropy similarity >0.75 of the raw spectra,
438 divided by the lowest injected quantity of compounds that yielded an MS/MS entropy similarity >0.75 of the
439 MS/MS spectra after the use of the benchmarked algorithms. A ratio less than 1 indicates that spectra gave
440 <0.75 MS/MS similarity after denoising, even for the injected quantities of compounds for which raw spectra
441 were annotated at MS/MS entropy similarity >0.75. Spectral entropy and entropy similarity were calculated
442 as published before^{21, 27}.

443

444 *Adding chemical and electronic noise ions to MS/MS spectra*

445 To test the robustness of the *Spectral Denoising* method against three benchmarking algorithms, chemical
446 noise and electronic noise were artificially added to all MS/MS spectra of the 240-compound mixtures with
447 absolute injected volumes from 200 pmol to 0.02 pmol. The relative intensity of both electronic and chemical
448 spectral noise I was generated using a Poisson distribution, demonstrated in equation (2):

449

$$f(I) = \frac{\lambda^I e^{-\lambda}}{I!} \quad (2)$$

450 Here, $f(I)$ represents the probability that a peak with relative intensity I will be generated, where $\lambda = 50$
451 characterizes the chemical noise and $\lambda = 5$ represents the electronic noise, to accurately mimic their
452 respective behaviors. For chemical noise, m/z values were randomly selected from a database of 3.5 million

453 formulas to ensure that only chemically feasible element ratios were used, with the additional constraint that
454 noise ions did not exceed the precursor m/z . Electronic noise m/z values were randomly sampled from a
455 uniform distribution ranging from 0 to the precursor ion m/z . If the calculated number of noise ions was not
456 an integer, it was rounded up to the nearest integer to ensure that at least one noise ion was generated for each
457 spectrum. The improvement in MS/MS entropy similarity scores was defined as the difference in entropy
458 similarity between the 500 pmol reference spectra and the contaminated raw spectra or the 500 pmol reference
459 spectra and the denoised spectra. The spectral entropy was calculated based on the 500 pmol reference spectra
460 as the ground truth.

461
462 Acquiring and annotating HILIC-MS/MS data from plasma of AD patients using Orbitrap Exploris 240 and
463 Orbitrap Astral mass analyzers with *Denoising Search*

464 The dataset comprised a subset of 20 plasma samples from an Alzheimer's patients exposome cohort, as part
465 of an exploratory study coordinated by Duke University under Prof. Rima Kaddurah-Daouk. Samples
466 underwent analysis using both the Orbitrap Exploris 240 and Orbitrap Astral systems (Thermo Scientific, San
467 Jose). The same hydrophilic interaction liquid chromatography (HILIC) method was employed for both
468 systems, employing a Waters ACQUITY Premier BEH Amide Column (1.7 μm , 2.1 mm x 50 mm). Gradient
469 elution used a biphasic system consisting of (a) water and (B) 95% acetonitrile, both buffered with 10 mM
470 ammonium formate and 0.125% formic acid. The gradient started at 100% phase B, reducing to 30% over
471 2.05 minutes, followed by an equilibration period back to 100% B over 0.65 minutes at 0.8 ml/min. For mass
472 spectrometry, the Exploris 240 Orbitrap was set to perform an MS1 full scan (60-900 m/z range, 60,000
473 resolution, $1e6$ AGC target, maximum injection time 100 ms) and a top-2 data-dependent MS/MS acquisition
474 (DDA) (15,000 resolution, $1e5$ AGC target, maximum injection time 10 ms, isolation window 1 m/z ,
475 normalized collision energies of 30-50-80%). The Astral system similarly conducted full scan MS1 (60-900
476 m/z range, 60,000 resolution, $1e6$ AGC target, maximum injection time 100 ms) and MS/MS scans (15,000
477 resolution, 1% of $1e5$ AGC target, maximum injection time 10 ms, isolation window 1 m/z , normalized
478 collision energy of 40%). Cycle time was 0.2 msec, which in Astral was equivalent to approximately top-35
479 DDA-MS/MS. Electrospray ionization settings: spray voltage 3500 v (+), sheath gas 60 arbitrary units,
480 auxiliary gas 20 arbitrary units, sweep gas 1 arbitrary unit, ion transfer tube temperature 350 $^{\circ}\text{C}$, vaporizer
481 temperature 400 $^{\circ}\text{C}$, RF lens 50%. Plasma samples were extracted by a biphasic solution of
482 MTBE/methanol/water as previously published⁴¹, and aliquots were dried and resuspended in 100 μL of
483 ACN:water (80:20) containing 30 isotope-labeled internal standards. 3 μl was injected. Pooled quality control
484 samples, including reference material NIST SRM1950 plasma and blank quality controls, were analyzed to
485 assess quantitative robustness and selectivity. Feature detection and alignment were performed using MS-
486 DIAL (version 4.9.2). Compound annotations were performed using combined repositories of NIST23,
487 Massbank.us, and GNPS libraries. Candidate spectra for identity search using entropy similarity and
488 *Denoising Search* were restricted to a precursor ion mass tolerance of 10 mDa. Compound superclass
489 information was assigned using the ClassyFire algorithm⁴².

490

491 **Data availability**

492 NIST Tandem Mass Spectral Library, 2023 release (NIST23) spectra are commercial available and
493 can be purchased from multiple vendors. MassBank of North America database (Massbank.us)
494 spectra can be freely downloaded from Massbank.us (<https://massbank.us/>). The metabolome

495 dataset of Alzheimer's Disease samples and the experimental data from the chemical dilution
496 series can be requested from the authors. Source data are provided with this paper.

497 **Code availability**

498 The code for calculating spectral denoising and denoising search can be found at GitHub
499 (https://github.com/FanzhouKong/spectral_denoising).

500

501 **Acknowledgments**

502 Samples were provided by the Alzheimer's Disease Metabolomics Consortium (ADMC) funded wholly or in
503 part by the following grants and supplements thereto: NIA R01AG046171, RF1AG051550, RF1AG057452,
504 R01AG059093, RF1AG058942, U01AG061359, U19AG063744 and FNIH: #DAOU16AMPA awarded to
505 Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such,
506 the investigators within the ADMC, not listed specifically in this publication's author's list, provided data
507 along with its preprocessing and prepared it for analysis, but did not participate in analysis or writing of this
508 manuscript. A complete listing of ADMC investigators can be found at:
509 <https://sites.duke.edu/adnimetab/team/>. TS, YL, FK and OF were supported by grants NIH U2C ES030158,
510 R03 OD03449, R01 HL157535 and U19 AG023122. The authors want to thank Dr. Elys Rodriguez for her
511 tremendous work on experimentation.

512

513 **References**

- 514 1. Virolainen, S. J.; VonHandorf, A.; Viel, K.; Weirauch, M. T.; Kottyan, L. C., Gene-environment
515 interactions and their impact on human health. *Genes Immun* **2023**, *24* (1), 1-11.
- 516 2. Rappaport, S. M.; Barupal, D. K.; Wishart, D.; Vineis, P.; Scalbert, A., The blood exposome and its role in
517 discovering causes of disease. *Environ Health Perspect* **2014**, *122* (8), 769-74.
- 518 3. Quinn, R. A.; Melnik, A. V.; Vrbanc, A.; Fu, T.; Patras, K. A.; Christy, M. P.; Bodai, Z.; Belda-Ferre,
519 P.; Tripathi, A.; Chung, L. K.; Downes, M.; Welch, R. D.; Quinn, M.; Humphrey, G.; Panitchpakdi, M.; Weldon,
520 K. C.; Aksenov, A.; da Silva, R.; Avila-Pacheco, J.; Clish, C.; Bae, S.; Mallick, H.; Franzosa, E. A.; Lloyd-Price,
521 J.; Bussell, R.; Thron, T.; Nelson, A. T.; Wang, M.; Leszczynski, E.; Vargas, F.; Gauglitz, J. M.; Meehan, M. J.;
522 Gentry, E.; Arthur, T. D.; Komor, A. C.; Poulsen, O.; Boland, B. S.; Chang, J. T.; Sandborn, W. J.; Lim, M.;
523 Garg, N.; Lumeng, J. C.; Xavier, R. J.; Kazmierczak, B. I.; Jain, R.; Egan, M.; Rhee, K. E.; Ferguson, D.;
524 Raffatellu, M.; Vlamakis, H.; Haddad, G. G.; Siegel, D.; Huttenhower, C.; Mazmanian, S. K.; Evans, R. M.; Nizet,
525 V.; Knight, R.; Dorrestein, P. C., Global chemical effects of the microbiome include new bile-acid conjugations.
526 *Nature* **2020**, *579* (7797), 123-129.
- 527 4. Di Minno, A.; Gelzo, M.; Stornaiuolo, M.; Ruoppolo, M.; Castaldo, G., The evolving landscape of
528 untargeted metabolomics. *Nutrition, Metabolism and Cardiovascular Diseases* **2021**, *31* (6), 1645-1652.
- 529 5. Petras, D.; Phelan, V. V.; Acharya, D.; Allen, A. E.; Aron, A. T.; Bandeira, N.; Bowen, B. P.; Belle-
530 Oudry, D.; Boecker, S.; Cummings, D. A.; Deutsch, J. M.; Fahy, E.; Garg, N.; Gregor, R.; Handelsman, J.;
531 Navarro-Hoyos, M.; Jarmusch, A. K.; Jarmusch, S. A.; Louie, K.; Maloney, K. N.; Marty, M. T.; Meijler, M. M.;
532 Mizrahi, I.; Neve, R. L.; Northen, T. R.; Molina-Santiago, C.; Panitchpakdi, M.; Pullman, B.; Puri, A. W.; Schmid,
533 R.; Subramaniam, S.; Thukral, M.; Vasquez-Castro, F.; Dorrestein, P. C.; Wang, M., GNPS Dashboard:
534 collaborative exploration of mass spectrometry data in the web browser. *Nature Methods* **2022**, *19* (2), 134-136.
- 535 6. Choi, M.; Carver, J.; Chiva, C.; Tzouros, M.; Huang, T.; Tsai, T.-H.; Pullman, B.; Bernhardt, O. M.;
536 Hüttenhain, R.; Teo, G. C.; Perez-Riverol, Y.; Muntel, J.; Müller, M.; Goetze, S.; Pavlou, M.; Verschueren, E.;
537 Wollscheid, B.; Nesvizhskii, A. I.; Reiter, L.; Dunkley, T.; Sabidó, E.; Bandeira, N.; Vitek, O., MassIVE.quant: a
538 community resource of quantitative mass spectrometry-based proteomics datasets. *Nature Methods* **2020**, *17* (10),
539 981-984.
- 540 7. Shin, H.; Sampat, M. P.; Bish, S. F.; Koomen, J. M.; Markey, M. K., Statistical characterization of chemical
541 noise in MALDI TOF MS by wavelet analysis of multiple noise realizations. *AMIA Annu Symp Proc* **2006**, *2006*,
542 1092.
- 543 8. Du, P.; Stolovitzky, G.; Horvatovich, P.; Bischoff, R.; Lim, J.; Suits, F., A noise model for mass
544 spectrometry based proteomics. *Bioinformatics* **2008**, *24* (8), 1070-7.

545 9. Busch, K. L., Chemical Noise in Mass Spectrometry. Part II — Effects of Choices in Ionization Methods on
546 Chemical Noise. In *Mass Spectrometry Forum*, 2002; Vol. 17:32–37.

547 10. Kaufmann, A.; Walker, S., Accuracy of relative isotopic abundance and mass measurements in a single-stage
548 orbitrap mass spectrometer. *Rapid Commun Mass Spectrom* **2012**, *26* (9), 1081-90.

549 11. Houel, S.; Abernathy, R.; Renganathan, K.; Meyer-Arendt, K.; Ahn, N. G.; Old, W. M., Quantifying the
550 Impact of Chimera MS/MS Spectra on Peptide Identification in Large-Scale Proteomics Studies. *Journal of Proteome*
551 *Research* **2010**, *9* (8), 4152-4160.

552 12. da Silva, R. R.; Dorrestein, P. C.; Quinn, R. A., Illuminating the dark matter in metabolomics. *Proc Natl*
553 *Acad Sci U S A* **2015**, *112* (41), 12549-50.

554 13. Awan, M. G.; Saeed, F., MS-REDUCE: an ultrafast technique for reduction of big mass spectrometry data for
555 high-throughput processing. *Bioinformatics* **2016**, *32* (10), 1518-26.

556 14. Xu, H.; Freitas, M. A., A Dynamic Noise Level Algorithm for Spectral Screening of Peptide MS/MS Spectra.
557 *BMC Bioinformatics* **2010**, *11* (1), 436.

558 15. Li, H.; Zong, N. C.; Liang, X.; Kim, A. K.; Choi, J. H.; Deng, N.; Zelaya, I.; Lam, M.; Duan, H.; Ping,
559 P., A novel spectral library workflow to enhance protein identifications. *J Proteomics* **2013**, *81*, 173-84.

560 16. Xing, S.; Yu, H.; Liu, M.; Jia, Q.; Sun, Z.; Fang, M.; Huan, T., Recognizing Contamination Fragment Ions
561 in Liquid Chromatography-Tandem Mass Spectrometry Data. *J Am Soc Mass Spectrom* **2021**, *32* (9), 2296-2305.

562 17. Zhao, T.; Xing, S.; Yu, H.; Huan, T., De Novo Cleaning of Chimeric MS/MS Spectra for LC-MS/MS-Based
563 Metabolomics. *Analytical Chemistry* **2023**, *95* (35), 13018-13028.

564 18. Stancliffe, E.; Schwaiger-Haber, M.; Sindelar, M.; Patti, G. J., DecoID improves identification rates in
565 metabolomics through database-assisted MS/MS deconvolution. *Nature Methods* **2021**, *18* (7), 779-787.

566 19. The Metabolomics Workbench, <https://www.metabolomicsworkbench.org/>. (accessed July 14).

567 20. Yang, X.; Neta, P.; Stein, S. E., Quality control for building libraries from electrospray ionization tandem
568 mass spectra. *Anal Chem* **2014**, *86* (13), 6393-400.

569 21. Li, Y.; Kind, T.; Folz, J.; Vaniya, A.; Mehta, S. S.; Fiehn, O., Spectral entropy outperforms MS/MS dot
570 product similarity for small-molecule compound identification. *Nat Methods* **2021**, *18* (12), 1524-1531.

571 22. Schiffman, C.; Petrick, L.; Perttula, K.; Yano, Y.; Carlsson, H.; Whitehead, T.; Metayer, C.; Hayes, J.;
572 Rappaport, S.; Dudoit, S., Filtering procedures for untargeted LC-MS metabolomics data. *BMC Bioinformatics* **2019**,
573 *20* (1), 334.

574 23. MZMine How do I determine the noise level in my data?
575 https://mzmine.github.io/mzmine_documentation/module_docs/featdet_mass_detection/mass-detection.html (accessed
576 May 14).

577 24. Miller, P. E.; Denton, M. B., The quadrupole mass filter: Basic operating concepts. *Journal of Chemical*
578 *Education* **1986**, *63* (7), 617.

579 25. Broeckling, C. D.; Beger, R. D.; Cheng, L. L.; Cumeras, R.; Cuthbertson, D. J.; Dasari, S.; Davis, W. C.;
580 Dunn, W. B.; Evans, A. M.; Fernández-Ochoa, A.; Gika, H.; Goodacre, R.; Goodman, K. D.; Gouveia, G. J.; Hsu,
581 P. C.; Kirwan, J. A.; Kodra, D.; Kuligowski, J.; Lan, R. S.; Monge, M. E.; Moussa, L. W.; Nair, S. G.; Reisdorph,
582 N.; Sherrod, S. D.; Ulmer Holland, C.; Vuckovic, D.; Yu, L. R.; Zhang, B.; Theodoridis, G.; Mosley, J. D., Current
583 Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples.
584 *Anal Chem* **2023**, *95* (51), 18645-18654.

585 26. Stravs, M. A.; Schymanski, E. L.; Singer, H. P.; Hollender, J., Automatic recalibration and processing of
586 tandem mass spectra using formula annotation. *Journal of Mass Spectrometry* **2013**, *48* (1), 89-99.

587 27. Fiehn, O.; Li, Y., Flash entropy search to query all mass spectral libraries in real time. **2023**.

588 28. Kind, T.; Fiehn, O., Seven Golden Rules for heuristic filtering of molecular formulas obtained by accurate
589 mass spectrometry. *BMC Bioinformatics* **2007**, *8* (1), 105.

590 29. Dührkop, K.; Scheubert, K.; Böcker, S., Molecular Formula Identification with SIRIUS. *Metabolites* **2013**, *3*
591 (2), 506-16.

592 30. Xing, S.; Huan, T., Radical fragment ions in collision-induced dissociation-based tandem mass spectrometry.
593 *Analytica Chimica Acta* **2022**, *1200*, 339613.

594 31. Shaffer, C. J.; Schröder, D.; Alcaraz, C.; Žabka, J.; Zins, E.-L., Reactions of Doubly Ionized Benzene with
595 Nitrogen and Water: A Nitrogen-Mediated Entry into Superacid Chemistry. *ChemPhysChem* **2012**, *13* (11), 2688-
596 2698.

597 32. Chen, Y.-W.; Lin, C.-J., Combining SVMs with Various Feature Selection Strategies. In *Feature Extraction:*
598 *Foundations and Applications*, Guyon, I.; Nikravesh, M.; Gunn, S.; Zadeh, L. A., Eds. Springer Berlin Heidelberg:
599 Berlin, Heidelberg, 2006; pp 315-324.

600 33. Xing, S.; Shen, S.; Xu, B.; Li, X.; Huan, T., BUDDY: molecular formula discovery via bottom-up MS/MS
601 interrogation. *Nature Methods* **2023**.

602 34. Dührkop, K.; Fleischauer, M.; Ludwig, M.; Aksenov, A. A.; Melnik, A. V.; Meusel, M.; Dorrestein, P. C.;
603 Rousu, J.; Böcker, S., SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure information.
604 *Nature Methods* **2019**, *16* (4), 299-302.

605 35. Zhu, C.; Pan, Z.; Du, B.; Liang, B.; He, Y.; Chen, H.; Liu, L.; Zeng, L., Massive Emissions of a Broad
606 Range of Emerging Hindered Phenol Antioxidants and Sulfur Antioxidants from E-Waste Recycling in Urban Mining:
607 New Insights into an Environmental Source. *Environmental Science & Technology Letters* **2022**, *9* (1), 42-49.

608 36. Tsugawa, H.; Kind, T.; Nakabayashi, R.; Yukihiro, D.; Tanaka, W.; Cajka, T.; Saito, K.; Fiehn, O.; Arita,
609 M., Hydrogen Rearrangement Rules: Computational MS/MS Fragmentation and Structure Elucidation Using MS-
610 FINDER Software. *Analytical Chemistry* **2016**, *88* (16), 7946-7958.

611 37. Bonini, P.; Kind, T.; Tsugawa, H.; Barupal, D. K.; Fiehn, O., Retip: Retention Time Prediction for
612 Compound Annotation in Untargeted Metabolomics. *Analytical Chemistry* **2020**, *92* (11), 7515-7522.

613 38. Nichols, C. M.; Dodds, J. N.; Rose, B. S.; Picache, J. A.; Morris, C. B.; Codreanu, S. G.; May, J. C.;
614 Sherrod, S. D.; McLean, J. A., Untargeted Molecular Discovery in Primary Metabolism: Collision Cross Section as a
615 Molecular Descriptor in Ion Mobility-Mass Spectrometry. *Analytical Chemistry* **2018**, *90* (24), 14484-14492.

616 39. Chen, Y.; Li, E. M.; Xu, L. Y., Guide to Metabolomics Analysis: A Bioinformatics Workflow. *Metabolites*
617 **2022**, *12* (4).

618 40. Kong, F.; Keshet, U.; Shen, T.; Rodriguez, E.; Fiehn, O., LibGen: Generating High Quality Spectral
619 Libraries of Natural Products for EAD-, UVPD-, and HCD-High Resolution Mass Spectrometers. *Analytical*
620 *Chemistry* **2023**.

621 41. Matyash, V.; Liebisch, G.; Kurzchalia, T. V.; Shevchenko, A.; Schwudke, D., Lipid extraction by methyl-
622 tert-butyl ether for high-throughput lipidomics. *J Lipid Res* **2008**, *49* (5), 1137-46.

623 42. Djoumbou Feunang, Y.; Eisner, R.; Knox, C.; Chepelev, L.; Hastings, J.; Owen, G.; Fahy, E.; Steinbeck,
624 C.; Subramanian, S.; Bolton, E.; Greiner, R.; Wishart, D. S., ClassyFire: automated chemical classification with a
625 comprehensive, computable taxonomy. *J Cheminform* **2016**, *8* (1), 61.

626

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [KongetalspectraldenoisingSupplementarymaterials07162024.pdf](#)